Navigation Links
Lone Star Value Issues Statement To Fellow Enzo Shareholders

NEW YORK, Dec. 29, 2015 /PRNewswire/ -- Lone Star Value Management, LLC, together with its affiliates and the other participants in its solicitation (collectively, "Lone Star Value", "LSV", "us", or "we"), owns approximately 600,000 shares common stock of Enzo Biochem, Inc. ("Enzo" or the "Company") (NYSE: ENZ), issued the following statement to Enzo shareholders today.

Dear Fellow Enzo Biochem Shareholders:

As you know, Lone Star Value, a long-term shareholder of Enzo, has been engaged in a proxy contest seeking the election of two highly-qualified director candidates to Enzo's Board of Directors. 

We have carefully reviewed the report issued by Institutional Shareholders Services (ISS) regarding its recommendation for the upcoming Annual Meeting of Enzo shareholders.  We are surprised by the significant and apparent mistakes in ISS' analysis and are disappointed in ISS' flawed determination.  We are also alarmed by the false accusations and anti-shareholder tactics freely employed by Enzo's incumbent directors in their adamant resistance to shareholder input in this election contest.  We further note that Enzo's incumbent directors seem entrenched and resistant to changing the Company's poor corporate governance or its related party transactions which we believe harm shareholder rights and shareholder value.

For us, this contest has always been about catalyzing positive change, initiating a thoughtful dialogue among Enzo shareholders regarding the future of our Company, and sending a message to the incumbent Board that they are directly responsible to shareholders, the true owners of the Company.  We have determined to withdraw our proxy contest at this time and will carefully monitor the Board's performance going forward in terms of improvements in financial performance, shareholder value creation, and corporate governance.  We do, however, want to set the record straight on a few points of importance:

The ISS report makes such obvious mistakes in its contorted choice of peer group that it undermines the credibility and impartiality of the report altogether.

Enzo has self-servingly changed its peer group three times in the past year with no apparent justification other than a blatant attempt to create a more favorable comparison.  For example, Enzo compiled a peer group in mid-December that they had never used before seemingly due solely to the initiation of our proxy contest.  Rather than use any reasonable group of peers for Enzo, including the peer group ISS had previously used itself in its report from the prior year, ISS chose to rely on Enzo's random selection of 11 companies that Enzo most recently patched together solely to make itself look more favorable.  Beyond making such a poor choice of peer group and failing to provide any justification for this choice, ISS decided to go against common practice and against common sense and compared Enzo to the median of this random group of 11 companies rather than the average as would have been far more sensible.  Notably, ISS uses a different peer group to compare Enzo to others for the purposes of examining executive compensation.  We are surprised and disappointed by this apparently partial determination which leads to the flawed and, in our view, unjustifiable conclusion that despite underperforming all peer groups and indices for almost any normal measurable period, Enzo does not need change.

Enzo's Board has played fast and loose with the truth in this contest but must hold itself to a higher standard in the future to earn credibility with shareholders

As noted above, we have decided to give Enzo's incumbents the chance to improve performance and corporate governance going forward and as such we do not want to engage in excessive back-and-forth over the numerous falsities to which Enzo has resorted in its efforts to ward off shareholder input.  Blatantly false comments regarding the track records of our nominees, John Climaco and Dimitrios Angelis, are extremely troubling to us.  That the Board would stop at nothing, including open disparagement of Messrs. Climaco and Angelis, playing fast and loose with the truth, and making numerous threats of tarnishing our nominees' reputation shows the depths to which the incumbents will go to avoid any fresh, independent, and outside perspective in the boardroom.  Directors of public companies are subject to high standards – truthfulness being one of the most important.  We urge the Board to hold itself to a higher standard in the future and not blindly follow the lead of a management team with a vested interest in maintaining the status quo.

Lone Star Value's Decision and Commitment to Fellow Shareholders

We initiated our proxy contest as a last resort effort in order to create positive change at Enzo, send a message to the current Board that they are accountable to shareholders rather than management, and initiate a healthy and much needed debate over the future of the Company and the urgency for improved performance and corporate governance.  This difficult but necessary debate has been initiated and we received tremendous shareholder input that the Company's financial performance and corporate governance needs to be improved.  Rather than waste more time and shareholder resources, we have determined to withdraw our proxy contest at this time to give the incumbent Board a chance to improve financial performance and corporate governance going forward.  We will continue to monitor the incumbents' progress and we intend to hold them accountable in the future for any failure to deliver improvement.  We thank our fellow shareholders for their encouragement and support for our efforts to enhance Enzo's Board and shareholder rights.  Proxies received by us to date that have not been revoked or revoted by the shareholders giving us such proxies, will be voted in accordance with the instructions provided to us.

Best Regards,

Jeffrey E. Eberwein

Lone Star Value Management, LLC

About Lone Star Value Management:
Lone Star Value Management, LLC ("Lone Star Value") is an investment firm that invests in undervalued securities and engages with its portfolio companies in a constructive way to help maximize value for all shareholders.  Lone Star Value was founded by Jeff Eberwein who was formerly a Portfolio Manager at Soros Fund Management and Viking Global Investors.  Lone Star Value is based in Old Greenwich, CT.

Investor Contact:
John Glenn Grau
(203) 972-9300 ext. 11

SOURCE Lone Star Value Management, LLC
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. SITC Among First to Address Value Proposition of Cancer Immunotherapy
2. Precision for Value Acquires Redwood Outcomes
3. Undervalued PharmaCyte Biotech Moves Closer to Phase 2b Clinical Trial Launch Featuring Breakthrough Technology
4. Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024
5. BioScrip Announces Steps To Enhance Shareholder Value
6. Half of healthcare payments to funnel through value-based care programs by 2020, Financial tools are top priority for ACOs, finds Black Book
7. Global Melanoma Therapeutics Market Value Forecast to Treble by 2020
8. Global Astaxanthin Market to Reach Value of USD 1.1 billion by 2020, Expects Industry Experts in New Report Available at
9. BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value
10. The Global EDIS Market Was Valued at $312.00 Million in 2014 - New Report by MarketsandMarkets
11. Global Smart Sensor Market in Building Automation is expected to reach a value of $1,415.6 million by 2018 - Report by MicroMarket Monitor
Post Your Comments:
(Date:8/29/2019)... ... August 29, 2019 , ... Prof. Stephen R. Byrn ... in Africa program, which includes a master’s degree in biotechnology innovation and regulatory ... through 13th, 2019. Topics to be addressed include Manufacturing, Quality, Regulation, Devices, ...
(Date:8/25/2019)... ... August 23, 2019 , ... Authors Gopal Nayak ... the scientific research book “Impact of Biofield Treatment on Growth and Anatomical Characteristics ... Patchouli. , The book garnered No. 1 status on Amazon in several ...
(Date:8/15/2019)... ... , ... PathSensors announced today that Roger Lawrence has joined ... of Food Technologists (IFT) Board of Directors, Illinois Institute of Technology (IIT) Institute ... and Applied Nutrition (JIFSAN) Advisory Council and the University of Maryland College of ...
(Date:8/8/2019)... , ... August 08, 2019 , ... ... Agents for sales and service organizations, today announced that the company’s Studio ... Award for the IVA market . Inference will officially accept the award at ...
Breaking Biology Technology:
(Date:8/27/2019)... JUPITER, Fla. (PRWEB) , ... August 27, 2019 ... ... developments in life science and drug development. This episode is scheduled to broadcast ... will explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show ...
(Date:8/23/2019)... (PRWEB) , ... August 22, 2019 , ... ... rebranding to Planet121 following their acquisition in June of 2018. Along with the ... and communications. , “Our goal was to create a cohesive brand that ...
(Date:8/21/2019)... ... August 20, 2019 , ... ... the second time since BioInformatics first fielded the survey in 2016. The ... Customer Experience , from BioInformatics, part of Science and Medicine Group. More than ...
Breaking Biology News(10 mins):